Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5316202
Max Phase: Preclinical
Molecular Formula: C61H86N10O9
Molecular Weight: 1103.42
Associated Items:
ID: ALA5316202
Max Phase: Preclinical
Molecular Formula: C61H86N10O9
Molecular Weight: 1103.42
Associated Items:
Canonical SMILES: CC(C)C[C@@H](/C=C/[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=O)OCc1ccccc1)C(=O)NCCCCCC1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1)C(C)C)NC(=O)OC(C)(C)C
Standard InChI: InChI=1S/C61H86N10O9/c1-40(2)37-45(66-59(78)80-60(5,6)7)30-29-44(38-42-21-11-8-12-22-42)56(76)71-36-19-28-49(71)54(74)69-50(41(3)4)55(75)67-48(27-18-34-64-58(77)79-39-43-23-13-9-14-24-43)53(73)63-33-16-10-15-31-61(32-20-35-65-61)57-68-47-26-17-25-46(52(62)72)51(47)70-57/h8-9,11-14,17,21-26,29-30,40-41,44-45,48-50,65H,10,15-16,18-20,27-28,31-39H2,1-7H3,(H2,62,72)(H,63,73)(H,64,77)(H,66,78)(H,67,75)(H,68,70)(H,69,74)/b30-29+/t44-,45-,48+,49+,50+,61?/m1/s1
Standard InChI Key: HGCPBYQTJFPZGA-UGFLPWHZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1103.42 | Molecular Weight (Monoisotopic): 1102.6579 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Borgini M, Wipf P.. (2023) Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition., 14 (5): [PMID:37197461] [10.1021/acsmedchemlett.3c00065] |
Source(1):